This activity was originally broadcast as a live virtual symposium during the 12th Annual Directions in Pharmacy conference series.
Program Description
Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease complications such as stroke or myocardial infarction. With more than 34 million US adults estimated to have hyperlipidemia, it is important for pharmacists to recognize key risk enhancers and engage patients in the treatment decision-making process. While lipid-lowering agents, particularly statins, have substantially reduced the burden of cardiovascular disease, in some cases, statin monotherapy may be insufficient or patients may experience statin intolerance and may require mono- or combination therapy with non-statin alternatives. This program will review efficacy and safety data associated with current and emerging non-statin agents and their use in clinical practice. By collaborating with multidisciplinary team members, providing patient education on risk factors and the role of newer, non-statin medications, and addressing potential barriers and challenges associated with statin therapy, pharmacists can have essential roles in promoting patient care and improving outcomes for patients with hyperlipidemia.
Target audience: Retail pharmacists and health-system pharmacists
Type of activity: Knowledge
Release date: June 20, 2022
Expiration date: June 20, 2023
Time to complete activity: 0.75 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Review the updated guidelines from the American Heart Association and the American College of Cardiology for the management and treatment of hyperlipidemia.
- Discuss the challenges associated with statin intolerance and efficacy and safety data associated with non-statin therapies including mechanisms of action, administration, dosing, and potential adverse effects.
- Recognize the role of the pharmacist as clinician and patient educator in the treatment and management of hyperlipidemia and in making clinical recommendations for non-statin therapies in appropriate patients.
Joseph Saseen, PharmD, BCPS, BCACP
Professor and Associate Dean for Clinical Affairs
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-22-308-H01-P. The activity is available for CE credit through June 20, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Joseph Saseen, PharmD, BCPS, BCACP, has no relevant financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Buszka, PharmD, BCPS; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.
An anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms